Search Results

Site Search

July 2023 - Molecular Pathology - Insights

This "Pathways" program provides a Clinical Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Molecular Pathology.

Mucopolysaccharidosis - Insights

Learn more about how Mayo Clinic Laboratories’ testing for mucopolysaccharidosis can assist with diagnosis and disease management.

Kelch-11 Autoantibody Test [Test in Focus] - Insights

Divyanshu (Div) Dubey, M.B.B.S., explains how Mayo Clinic Labs’ new Kelch-11 antibody test — the first in the world — can confirm diagnosis, guide treatment, and improve outcomes in patients affected by testicular cancer-associated...

Examining dendritic cells to uncover immunity defects - Insights

Dendritic cells play a crucial role in the body's immune response. Research has shown that too few of these cells in the blood may signal a defect in innate immunity. Up to this point, however, no clinical test has been available to count...

Hot Topic Archives - Insights

Skip to Content MayoACCESS MayoLINK...

5 Tips for Effectively Surveying Lab Customers - Insights

Surveys are crucial for strengthening laboratory operations. Get insights for how to make them as effective as possible.

Hot Topic Archives - Page 2 of 6 - Insights

Skip to Content MayoACCESS MayoLINK...

Hot Topic Archives - Page 3 of 6 - Insights

Skip to Content MayoACCESS MayoLINK...

Test detects autoimmune neurology disorders linked to cancer: Sean Pittock, M.D. - Insights

Sean Pittock, M.D., explains how Mayo Clinic Laboratories' novel Ma2 test aids diagnosis of autoimmune neurology disorders that are often caused by underlying cancer. Rapid diagnosis is key to preventing significant disability and disease.

Addiction rehab monitoring assay - Insights

Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories' unique approach to urine drug testing for addiction rehabilitation. Designed to guide and monitor therapy, the comprehensive profile tests for the most...